Use of Ointments in Prevention of Catheter Related Infections in PD
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in
approximately 25% of patients requiring dialysis in Canada. The most common complication is
bacterial infection or 'peritonitis'. Peritonitis causes severe acute abdominal pain and may
lead to failure of peritoneal dialysis treatment, hospitalization or death, particularly if
left untreated. Amongst the strategies used to prevent peritonitis, patients are instructed
on the regular use of a prophylactic ointment around the point where the catheter exits from
the body. At the present time most centers in Canada routinely prescribe mupirocin ointment
for use at the exit site, however newer ointments have become available. One such ointment is
Polysporin Triple. The aim of this study is to determine if catheter related infections can
be significantly reduced by the routine application of Polysporin Triple in comparison to
mupirocin ointment. A multi-centre, randomized, double blind, controlled study is proposed.
Participants will be randomized to either mupirocin or Polysporin Triple and followed for 18
months or until the first catheter related infection, death or catheter removal. The
difference in catheter related infection rates will be compared between the two groups. We
anticipate the results of this study will allow clinicians to prescribe the ointment most
likely to reduce infections. By doing so this will reduce the complication rate associated
with peritoneal dialysis and, ultimately improve survival.